Drug Type Monoclonal antibody |
Synonyms SEA-TGT, SGN TGT, SEA TGT + [2] |
Target |
Action inhibitors |
Mechanism TIGIT inhibitors(T cell immunoglobulin and ITIM domains inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Esophageal Carcinoma | Phase 1 | United States | 29 May 2020 | |
Esophageal Carcinoma | Phase 1 | France | 29 May 2020 | |
Esophageal Carcinoma | Phase 1 | Italy | 29 May 2020 | |
Esophageal Carcinoma | Phase 1 | Spain | 29 May 2020 | |
Esophageal Carcinoma | Phase 1 | United Kingdom | 29 May 2020 | |
Hodgkin's Lymphoma | Phase 1 | United States | 29 May 2020 | |
Hodgkin's Lymphoma | Phase 1 | France | 29 May 2020 | |
Hodgkin's Lymphoma | Phase 1 | Italy | 29 May 2020 | |
Hodgkin's Lymphoma | Phase 1 | Spain | 29 May 2020 | |
Hodgkin's Lymphoma | Phase 1 | United Kingdom | 29 May 2020 |